<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049265</url>
  </required_header>
  <id_info>
    <org_study_id>JS007-001-I</org_study_id>
    <nct_id>NCT05049265</nct_id>
  </id_info>
  <brief_title>Clinical Study of JS007 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase Ia Study to Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single-dose and Multiple-dose Of JS007 Injection In Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, phase Ia clinical study to evaluate the safety, tolerability,&#xD;
      pharmacokinetic (PK) profile, pharmacodynamic (PD) profile, immunogenicity and preliminary&#xD;
      efficacy of JS007 in the patients with advanced solid tumors who have progressed after&#xD;
      standard of care, or lack of effective standard therapeutic regimen. This study is divided&#xD;
      into two periods: dose escalation period, dose expansion period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2021</start_date>
  <completion_date type="Anticipated">September 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>The maximum tolerated dose (MTD) is defined as the highest dose at which DLT （Dose-Limiting Toxicity）occurs in &lt;1/3 subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>21 days after first infusion of study drug</time_frame>
    <description>DLT is defined as any of the specified toxicities evaluated as at least possibly related with the study drug within 21 days after the first dose (NCI-CTCAE v5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>AE is assessed according to NCI-CTCAE 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>SAE（Serious adverse event） is assessed according to NCI-CTCAE 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of immune-related adverse events (irAE)</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>IrAE is assessed according to NCI-CTCAE 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>severity of immune-related adverse events (irAE)</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>IrAE is assessed according to NCI-CTCAE 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>peak concentration (Cmax)</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters peak concentration (Cmax);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>trough concentration (Ctrough)</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters trough concentration (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to peak (Tmax)</measure>
    <time_frame>Up to 18 approximately months</time_frame>
    <description>Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters time to peak (Tmax);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the plasma drug concentration-time curve (AUC0-t )</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters area under the plasma drug concentration-time curve (AUC0-t )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the plasma drug concentration-time curve (AUC0-inf)</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters area under the plasma drug concentration-time curve (AUC0-inf);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>elimination half-life (t1/2)</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters elimination half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clearance rate (CL)</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters clearance rate (CL);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent volume of distribution(Vd)</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; apparent volume of distribution(Vd)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>volume of distribution (Vss)</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters volume of distribution (Vss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean retention time (MRT)</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters mean retention time (MRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of lymphocyte in peripheral blood before and after administration</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>The number of lymphocyte in peripheral blood before and after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of lymphocyte in peripheral blood before and after administration</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>The proportion of lymphocyte in peripheral blood before and after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-drug body (ADA)</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>incidence of anti-drug body (ADA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neutralizing antibody (Nab)</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>incidence of neutralizing antibody (Nab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neutralizing antibody (Nab)</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>concentration of neutralizing antibody (Nab)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ORR</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>The efficacy evaluated by the investigator in accordance with RECIST 1.1 criteria (solid tumors), including objective response rate (ORR).</description>
  </other_outcome>
  <other_outcome>
    <measure>DOR</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>The efficacy evaluated by the investigator in accordance with RECIST 1.1 criteria (solid tumors) , including duration of response (DOR);</description>
  </other_outcome>
  <other_outcome>
    <measure>DCR</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>The efficacy evaluated by the investigator in accordance with RECIST 1.1 criteria (solid tumors) , including disease control rate (DCR);</description>
  </other_outcome>
  <other_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>The efficacy evaluated by the investigator in accordance with RECIST 1.1 criteria (solid tumors) , including progression-free survival (PFS)</description>
  </other_outcome>
  <other_outcome>
    <measure>OS</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>The efficacy evaluated by the investigator in accordance with RECIST 1.1 criteria (solid tumors) , including overall survival (OS);</description>
  </other_outcome>
  <other_outcome>
    <measure>CTLA-4（cytotoxic T lymphocyte-associated antigen-4）</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>Expression of CTLA-4 in tumor tissues before administration</description>
  </other_outcome>
  <other_outcome>
    <measure>FoxP3（transcription factor Forkhead box P3）</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>Expression of FoxP3 in tumor tissues before administration</description>
  </other_outcome>
  <other_outcome>
    <measure>IDO（(indoleamine 2,3-dioxy- genase）</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>Expression of IDO in tumor tissues before administration</description>
  </other_outcome>
  <other_outcome>
    <measure>mutation of immune related genes in tumor tissues before administration</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>mutation of immune related genes in tumor tissues before administration</description>
  </other_outcome>
  <other_outcome>
    <measure>expression of immune related genes in tumor tissues before administration</measure>
    <time_frame>Up to 12 approximately months</time_frame>
    <description>expression of immune related genes in tumor tissues before administration</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Patients With Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>JS007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JS007</intervention_name>
    <description>JS007 only</description>
    <arm_group_label>JS007</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Male or female patients with age of 18~75 years;&#xD;
&#xD;
          2. Signed informed consent form;&#xD;
&#xD;
          3. Confirmed histological or cytological diagnosis of advanced or recurrent solid tumor&#xD;
             with previous standard therapy failure, no available standard therapy or refusal of&#xD;
             standard therapy;&#xD;
&#xD;
          4. Consent to provide tumor tissue (FFPE archival sample within 2 years, or newly&#xD;
             obtained tissue blocks, or unstained slides from FFPE);&#xD;
&#xD;
          5. Having at least one measurable lesion in accordance with the response evaluation&#xD;
             criteria in solid tumors (RECIST V1.1).&#xD;
&#xD;
          6. Life expectancy ≥ 3 months;&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) Performance Status score 0 or 1 (Appendix&#xD;
             1);&#xD;
&#xD;
          8. Functional indicators of organs must fulfill the following criteria:&#xD;
&#xD;
             i. White blood cell ≥ 2.5 × 109/L ii. Neutrophils ≥ 1.5 × 109/L iii. Platelets ≥ 85 ×&#xD;
             109/L iv. Hemoglobin ≥ 90 g/L v. Blood creatinine ≤ 1.5 × ULN, or creatinine clearance&#xD;
             &gt; 40 ml/min (calculated according to Cockcroft-Gault formula, see Appendix) vi.&#xD;
             Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 × ULN (for&#xD;
             known liver metastases: AST and ALT ≤ 5×ULN) vii. Total bilirubin ≤ 1.5 × ULN (For&#xD;
             subjects with Gilbert's Syndrome or known liver metastases, ≤ 2×ULN is acceptable)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. The patient with metastasis to the central nervous system (CNS);&#xD;
&#xD;
          2. The patient requires systemic steroids or anti-convulsant drugs, or patients with risk&#xD;
             of intracerebral hemorrhage judged by the investigator;&#xD;
&#xD;
          3. Patients with primary CNS tumor or meningeal metastasis;&#xD;
&#xD;
          4. Having used systemic anticancer therapy, including radiotherapy, chemotherapy, hormone&#xD;
             therapy, surgery, or molecular targeted therapy, within 4 weeks prior to the first&#xD;
             dose, or all adverse events except hair loss have not recovered to CTCAE Grade 1 or&#xD;
             below;&#xD;
&#xD;
          5. Having other not curable cancers in the past 5 years, excluding the cured or treatable&#xD;
             ones, such as basal skin carcinoma, squamous cell skin carcinoma, superficial bladder&#xD;
             carcinoma, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in&#xD;
             situ, etc;&#xD;
&#xD;
          6. Active autoimmune diseases required systemic treatment in the past 2 years, excluding&#xD;
             vitiligo, type I diabetes, and autoimmune thyroiditis indued hypothyroidism that is&#xD;
             curable by thyroid hormone replacement therapy;&#xD;
&#xD;
          7. Active tuberculosis (TB);&#xD;
&#xD;
          8. Confirmed infection of human immunodeficiency virus (HIV) or acquired immunodeficiency&#xD;
             syndrome (AIDS);&#xD;
&#xD;
          9. Active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV):&#xD;
&#xD;
               1. HBsAg positive and HBV DNA ≥ 1000 IU/mL;&#xD;
&#xD;
               2. Positive test results of HCV RNA.&#xD;
&#xD;
         10. Women who are pregnant or breastfeeding;&#xD;
&#xD;
         11. Patients who are unavailable for venipuncture and/or intolerable for intravenous&#xD;
             catheterization;&#xD;
&#xD;
         12. Interstitial lung disease;&#xD;
&#xD;
         13. History or basis of any clinically significant cardiovascular diseases as follows:&#xD;
             abnormal electrocardiogram indicating additional risk for patients at the discretion&#xD;
             of investigator; history of congestive heart failure (CHF) of grade III or above as&#xD;
             documented by New York Heart Association (NYHA) criteria; history of cerebral&#xD;
             infarction or myocardial infarction within 3 months prior to first dose; uncontrolled&#xD;
             hypertension (systolic blood pressure &gt; 160 mmHg or diastolic blood pressure &gt; 100&#xD;
             mmHg); unstable angina; serious uncontrolled arrhythmia; baseline left ventricular&#xD;
             ejection fraction (LVEF) &lt; 50% or cardiac wall motion abnormalities identified by&#xD;
             echocardiogram (ECHO).&#xD;
&#xD;
         14. Patients accepting other study drugs or anti-infective vaccine (e.g., influenza&#xD;
             vaccine, and varicella vaccine) within 28 days prior to the first dose, and COVID-19&#xD;
             （Corona Virus Disease 2019）vaccine is permitted&#xD;
&#xD;
         15. Patients with anti-tumor vaccine therapy within 3 months prior to the first dose, and&#xD;
             prophylactic HPV（human papilloma virus） vaccine is permitted;&#xD;
&#xD;
         16. Previous treatment with anti-CTLA-4 drugs;&#xD;
&#xD;
         17. Patients accepting systemic corticosteroids treatment at the doses of&#xD;
             immunosuppressive effects (prednisone &gt; 10 mg/day or equivalent level) within 2 weeks&#xD;
             before the first dose; patients accepting immunosuppressive agents or glucocorticoids&#xD;
             (at doses equivalent to prednisone &gt; 10 mg/day) within 2 weeks before the first dose.&#xD;
             Note: Epinephrine replacement therapy (equivalent to prednisone ≤ 10 mg/day) is&#xD;
             allowed for patients without active immune disorder . Topical, intraocular,&#xD;
             intra-articular, intranasal, and inhaled corticosteroids, which lead to (low systemic&#xD;
             absorption, are allowed; short-term corticosteroids treatment is allowed for&#xD;
             prophylactic therapy (e.g., be allergic to contrast media) or non-autoimmune diseases&#xD;
             (e.g., delayed hypersensitivity reactions after exposure to allergens).&#xD;
&#xD;
         18. Patient accepting any antitumor traditional Chinese patent medicine within 2 weeks&#xD;
             prior to the first dose (any antitumor traditional Chinese patent medicine is&#xD;
             prohibited during this study).&#xD;
&#xD;
         19. Active infection requiring systematic treatment/antibiotics. Patient accepting&#xD;
             intravenous anti-infective therapy with one week prior to the first dose or undergoing&#xD;
             systematic anti-infective agents ≥ 7 days;&#xD;
&#xD;
         20. Received live attenuated vaccines within 4 weeks prior to the first dose, or plan to&#xD;
             receive live attenuated vaccines during the study;&#xD;
&#xD;
         21. Allergic to any component of JS007;&#xD;
&#xD;
         22. Patients are not ineligible if meet at least one of the following conditions prior to&#xD;
             the first dose :&#xD;
&#xD;
             i. Major surgery requiring general anesthesia within 4 weeks prior to the first dose;&#xD;
             ii. Surgery requiring local/epidural anesthesia within 72 hours prior to the first&#xD;
             dose; iii. Skin biopsy requiring local anesthesia within 1 hour prior to the first&#xD;
             dose.&#xD;
&#xD;
         23. Patients who are not appropriate for this trial due to other reasons at the discretion&#xD;
             of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pan He, Postgraduate</last_name>
    <phone>8615172333540</phone>
    <email>pan_he@junshipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medical</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yan Shi, PhD</last_name>
      <email>shibaiwan12@vip.sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

